MCB Clinical Research Centers | Colorado Springs, CO
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI]) in all participants with major depressive disorder (MDD).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Transferred-entry participants:
-Participants must have completed the double blind (DB) (expand DB) Treatment Phase of Study 67953964MDD3001 or Study 67953964MDD3002 without early treatment discontinuation or switch in the oral selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in the parent study
Direct-entry participants:
Direct-entry and Transferred-entry Participants:
-Participants should not take any prohibited medication or food supplements
Exclusion criteria
Transferred-entry Participants:
Direct-entry Participants:
Primary purpose
Allocation
Interventional model
Masking
840 participants in 1 patient group
Loading...
Central trial contact
Study Contact
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal